Gilead Sciences partners with EVOQ Therapeutics on immunotherapies
American biopharma major Gilead Sciences and immunotherapy company EVOQ Therapeutics have entered into a partnership to develop and market immunotherapy products. Under the collaboration and licensing agreement, Gilead Sciences will acquire the exclusive license for EVOQ Therapeutics’ NanoDisc technology to pursue product candidates for rheumatoid arthritis and lupus treatment. As per the agreement, EVOQ Therapeutics […]
